TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:43
Aldeyra Therapeutics Inc. ( ALDX ) https://www.aldeyra.com
2.92USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-68.03%
ALDX
SPY
32.74%
-73.79%
ALDX
SPY
92.93%
-67.61%
ALDX
SPY
224.41%
ALDX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
171.67
28.84
0.24
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.88
7.03
1.43
-9.88
0.00
-0.65
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.3126
-33.40
-26.17
1.62
Other Earnings and Cash Flow Stats:
Aldeyra Therapeutics Inc. ( ALDX ) Net Income TTM ($MM) is -49.54
Aldeyra Therapeutics Inc. ( ALDX ) Operating Income TTM ($MM) is -54.83
Aldeyra Therapeutics Inc. ( ALDX ) Owners' Earnings Annual ($MM) is -42.11
Aldeyra Therapeutics Inc. ( ALDX ) Current Price to Owners' Earnings ratio is -4.11
Aldeyra Therapeutics Inc. ( ALDX ) EBITDA TTM ($MM) is -50.70
Aldeyra Therapeutics Inc. ( ALDX ) EBITDA Margin is 0.00%
Capital Allocation:
Aldeyra Therapeutics Inc. ( ALDX ) has paid 0.00 dividends per share and bought back -0.790054 million shares in the past 12 months
Aldeyra Therapeutics Inc. ( ALDX ) has reduced its debt by 16.734332 million USD in the last 12 months
Capital Structure:
Aldeyra Therapeutics Inc. ( ALDX ) Interest-bearing Debt ($MM) as of last quarter is 0
Aldeyra Therapeutics Inc. ( ALDX ) Annual Working Capital Investments ($MM) are 4
Aldeyra Therapeutics Inc. ( ALDX ) Book Value ($MM) as of last quarter is 119
Aldeyra Therapeutics Inc. ( ALDX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Aldeyra Therapeutics Inc. ( ALDX ) has 143 million in cash on hand as of last quarter
Aldeyra Therapeutics Inc. ( ALDX ) has 22 million of liabilities due within 12 months, and long term debt 17 as of last quarter
Aldeyra Therapeutics Inc. ( ALDX ) has 59 common shares outstanding as of last quarter
Aldeyra Therapeutics Inc. ( ALDX ) has 0 million USD of preferred stock value
Academic Scores:
Aldeyra Therapeutics Inc. ( ALDX ) Altman Z-Score is -0.12 as of last quarter
Aldeyra Therapeutics Inc. ( ALDX ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Aldeyra Therapeutics Inc. ( ALDX ) largest shareholder is Northern Trust Corp owning 412444 shares at 1.21 ($MM) value
Todd C Brady(an insider) Sold 97914 shares of Aldeyra Therapeutics Inc. ( ALDX ) for the amount of $320178.78 on 2024-03-11
2.01% of Aldeyra Therapeutics Inc. ( ALDX ) is held by insiders, and 61.20% is held by institutions
Aldeyra Therapeutics Inc. ( ALDX ) went public on 2014-05-02
Other Aldeyra Therapeutics Inc. ( ALDX ) financial metrics:
FCF:-41.33
Unlevered Free Cash Flow:-48.16
EPS:-0.55
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-27.34
Beta:1.62
Buffet's Owners Earnings:-42.11
Price to Owner's Earnings:-4.11
About Aldeyra Therapeutics Inc. ( ALDX ) :
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.